Revenue for BrainAurora significantly increased in the initial half of 2025, though the company's losses expanded during the same period.
BrainAurora Medical Technology Ltd., a leading company in the field of brain science and AI, has reported impressive growth in its operations for the first half of the year. The company announced a 92.8% year-on-year increase in revenue, reaching 100 million yuan ($14 million).
This growth was driven by several factors, including an increase in the number of hospitals purchasing BrainAurora's cognitive impairment digital therapy system. The number of hospitals using the system rose from 186 to 205, demonstrating a growing demand for BrainAurora's innovative solutions.
In addition, the number of patients using the system at home also saw a significant increase, with the figure now standing at 12,915. The total number of sessions conducted also rose, from about 1.8 million to 2.59 million.
One of the key contributors to BrainAurora's revenue was its medical AI large language model solutions, which brought in over 240 million yuan.
However, the company has faced some challenges. Dr. Wang Xiaoyi, the former CEO of BrainAurora, resigned from his positions as executive director, CEO, and chief R&D officer in June, citing depression as the reason. The company has yet to announce a successor to Dr. Wang.
Despite this, BrainAurora's stock opened flat on Friday and closed at HK$5.36 by the midday break, down 1.89%.
For those interested in staying updated on the latest news in the field of brain science and AI, subscribe to our weekly free newsletter by clicking here.
Read also:
- Understanding Hemorrhagic Gastroenteritis: Key Facts
- Stopping Osteoporosis Treatment: Timeline Considerations
- Tobacco industry's suggested changes on a legislative modification are disregarded by health journalists
- Expanded Community Health Involvement by CK Birla Hospitals, Jaipur, Maintained Through Consistent Outreach Programs Across Rajasthan
